Highlights Daiichi Sankyo Company, Limited

Equities

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 12:00:00 12/03/2026 pm IST			5-day change	1st Jan Change
2,900.00 ^JPY	+1.59%		+1.97%	-13.38%

10/03	AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu	CI
09/03	UK Shares Start Week in Red as Oil Prices Surge Amid US-Iran War	MT

Highlights

10/03	AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu	CI
09/03	Astra drug wins US review as oil surges above USD100	AN
09/03	Daiichi Sankyo says Enhertu gets U.S. Priority Review for HER2-positive early breast cancer	RE
09/03	AstraZeneca, Daiichi Sankyo's Enhertu Receives US FDA Priority Review Status in Early Breast Cancer	MT
09/03	Daiichi Sankyo And AstraZeneca Announce Acceptance And Priority Review Of Supplemental Biologics License Application For ENHERTU For HER2 Positive Breast Cancer	CI
27/02	Daiichi Sankyo Submits Supplemental New Drug Application for Enhertu as Adjuvant Therapy for Her2 Positive Early Breast Cancer in Japan	CI
24/02	Avacta hails new data supporting proprietary preCision platform	AN
24/02	Avacta's pre\|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis	CI
23/02	SylamoreBio Announces Research Collaboration with Daiichi Sankyo to Advance SyLEC Delivery Technology	CI
20/02	Risk on, risk off
19/02	IHH Healthcare says on Feb 12 NTK submitted petition to further amend NTK's claim against Daiichi Sankyo	RE
19/02	European Medicines Agency Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer	CI
19/02	IHH Healthcare's Subsidiary Files Petition to Amend Lawsuit	MT
19/02	AstraZeneca, Daiichi Sankyo EU Application Validated for Breast Cancer Treatment	MT
19/02	ENHERTU Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer	CI
17/02	BostonGene Announces Strategic Collaboration with Daiichi Sankyo to Accelerate Drug Development Through AI-Driven Multimodal Analytics	CI
12/02	Daiichi Sankyo Submits Supplemental New Drug Application to Japan's Ministry of Health, Labour and Welfare for DATROWAY	CI
04/02	Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial	CI
03/02	Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S	CI
03/02	AstraZeneca, Daiichi Sankyo's Breast Cancer Treatment Wins US Priority Review Status	MT
30/01	Daiichi Sankyo's Nine-Month Profit Rises 4%	MT
30/01	Daiichi Sankyo Company, Limited Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
28/01	Berenberg Ups AstraZeneca Price Target on Datroway's Sales Potential in Lung Cancer	MT
22/01	National Medical Products Administration Approves Enhertu in China as the First and Only Her2 Directed Dc for the Second-Line Treatment of Patients with Her2 Positive Metastatic Gastric Cancer	CI
20/01	European Stocks Close Lower in Tuesday Trading; UK Unemployment Rises to 5.1%	MT